InspireMD (NSPR) Cash & Equivalents (2010 - 2025)

InspireMD's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $8.9 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 52.74% year-over-year to $8.9 million in Q4 2025; TTM through Dec 2025 was $8.9 million, a 52.74% decrease from a year earlier, with the FY2025 full-year figure at $8.9 million, down 52.74% from the prior year.
• Cash & Equivalents slipped to $8.9 million in Q4 2025 per NSPR's latest filing, from $63.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $63.4 million in Q3 2025 and bottomed at $3.9 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $11.8 million (2021), against an average of $17.1 million.
• Across the five-year window, Cash & Equivalents soared 1301.91% in 2021 and plunged 84.57% in 2022, its largest moves.
• Year by year, Cash & Equivalents stood at $12.0 million in 2021, then slumped by 61.41% to $4.6 million in 2022, then surged by 108.12% to $9.6 million in 2023, then soared by 96.22% to $18.9 million in 2024, then plunged by 52.74% to $8.9 million in 2025.
• Per Business Quant, the three latest NSPR Cash & Equivalents figures stand at $8.9 million (Q4 2025), $63.4 million (Q3 2025), and $11.5 million (Q2 2025).